UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________________________________
FORM 6-K
_________________________________________________________
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
Dated November 10, 2020
Commission File Number 001-36421
_________________________________________________________
AURINIA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)
_________________________________________________________
N/A
(Translation of Registrant's Name)
#1203-4464 Markham Street
Victoria, British Columbia
V8Z 7X8
(250) 708-4272
(Address and telephone number of registrant’s principal executive offices)
_________________________________________________________
Indicate by check mark whether the registrant files of will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☐ Form 40-F ☒
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7): ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☒ No ☐
This Form 6-K is hereby filed and incorporated by reference in the registrant's Registration Statement on Form F-10 (File No. 333-238785).
_________________________________________________________
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
| | |
Date: November 10, 2020 | Aurinia Pharmaceuticals Inc. |
| | |
| By: | /s/ Joseph Miller |
| Name: Title: | Joseph Miller Chief Financial Officer |
EXHIBIT INDEX
|
| |
Exhibit No. | Document |
| Interim Condensed Consolidated Financial Statements for the Third Quarter ended September 30, 2020 |
| MD&A for the Third Quarter ended September 30, 2020 |
| Certification of Interim Filings - Chief Executive Officer |
| Certification of Interim Filings - Chief Financial Officer |
Exhibits 99.1, 99.2, 99.3 and 99.4 included with this report on Form 6-K are hereby incorporated by reference as exhibits to the Registration Statement on Form F-10 of Aurinia Pharmaceuticals Inc. (File No. 333-238785), as amended or supplemented.